What is OUTLOOK THERAPEUTICS INC (OTLK) stock price today?

OUTLOOK THERAPEUTICS INC (OTLK) currently trades at $0.25 per share. The stock has a market capitalization of $34.41M and a P/E ratio of —x.

Is OTLK stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, OUTLOOK THERAPEUTICS INC has a Smart Value Score of 33/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -47.47.

What is OUTLOOK THERAPEUTICS INC's revenue and earnings?

OUTLOOK THERAPEUTICS INC has trailing twelve-month (TTM) revenue of $205700.00 with profit margins of 0.00%. Earnings per share (EPS) is $-2.89.

Is OUTLOOK THERAPEUTICS INC financially healthy?

OUTLOOK THERAPEUTICS INC's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -47.47 places it in the distress.

OTLK

OUTLOOK THERAPEUTICS INC

NASDAQ: OTLK · HEALTHCARE · BIOTECHNOLOGY

$0.25

-2.50% today

Updated 2026-04-30

Market cap

$34.41M

P/E ratio

—

P/S ratio

167.29x

EPS (TTM)

$-2.89

Dividend yield

—

52W range

$0 – $3

Volume

3.6M

Market cap

$34.41M

P/E ratio

—

P/S ratio

167.29x

EPS (TTM)

$-2.89

Dividend yield

—

52W range

$0 – $3

Volume

3.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.3

Growth

4.5

Quality

4.5

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-47.5

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$4.17

+1566.80%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 658.00% QoQ

+ Debt/equity -0.01x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -47.47 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-14.94T

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$170124.00	$1.41M	$205700.00
Net income	$-66.05M	$-58.98M	$-75.37M	$-62.42M	$-23.06M
EPS	—	—	—	—	$-2.89
Free cash flow	$-56.67M	$-42.97M	$-68.79M	$-51.83T	$-14.94T
Profit margin	—	—	-44,301.22%	-4,416.22%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
OTLK	$34.41M	33	6.3	4.5	5.0	4.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

OUTLOOK THERAPEUTICS INC trades at $0.25. Our Smart Value Score of 33/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -47.47, it sits in the distress. TTM revenue stands at $205700.00.

Frequently asked questions

What is OUTLOOK THERAPEUTICS INC's stock price?

OUTLOOK THERAPEUTICS INC (OTLK) trades at $0.25.

Is OUTLOOK THERAPEUTICS INC overvalued?

Smart Value Score 33/100 (Grade F, Strong Sell).

What is the price target of OUTLOOK THERAPEUTICS INC (OTLK)?

The analyst target price is $4.17, representing +1566.8% upside from the current price of $0.25.

What is OUTLOOK THERAPEUTICS INC's revenue?

TTM revenue is $205700.00.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-47.47 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

outlooktherapeutics.com

Quick metrics

P/S ratio167.29x

ROE-3.65%

Beta0.19

50D MA$0.33

200D MA$1.16

Shares out0.12B

Float0.07B

Short ratio—

Avg volume3.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

OTLK vs LLY →OTLK vs JNJ →OTLK vs ABBV →Stock screener →